Ovarian CancerNCT05011539
Thiol-disulfide Homeostasis in Patients With Ovarian Cancer
An observational study of Ovarian Cancer, run by Tepecik Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Ovarian cancer is the third most common after endometrial and cervical cancer in societies with a high standard of living; It is the second most common type of gynecological cancer after cervical cancer in societies with a low standard of living, and it is also the deadliest among gynecological cancers. Read more about this study
- Who is it for?
- Any age, women onlyHealthy volunteers can take part
- Conditions the study is for
- Ovarian Cancer
- How many people
- 115 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 9 Apr 2021to 1 May 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Ovarian cancer patients who applied to Izmir Tepecik Training and Research Hospital
Who may be able to join
- Histopathological diagnosis of ovarian cancer
Who cannot join
- Having an acute or chronic disease that will cause oxidative stress
- Using alcohol/cigarettes/drugs
- Using antioxidant agents (such as vitamins A, C, E)
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Izmir Tepecik Training and Research Hospital
Izmir, Konak, 35020
About this study
Ovarian cancer is the third most common after endometrial and cervical cancer in societies with a high standard of living; It is the second most common type of gynecological cancer after cervical cancer in societies with a low standard of living, and it is also the deadliest among gynecological cancers. Dynamic thiol-disulfide homeostasis is an antioxidant system that minimizes oxidative damage and prevents cell damage. In the presence of oxidative stress, the thiol groups combine to form the disulfide structure, and when the oxidative stress condition is over, they are separated into thiol groups again. This homeostasis is impaired in conditions that cause oxidative processes such as diabetes, cardiovascular diseases, cancers, rheumatoid arthritis, and chronic kidney failure. This can be determined by measuring the total thiol and native thiol levels. Likewise, the level of ischemia modified albumin increases in the case of oxidative stress. There are studies on this homeostasis in the literature on many types of cancer; There are studies on endometrial cancer and cervical cancer, which are gynecological cancers In this study, the usability of these tests together with other diagnostic tests in the diagnosis of ovarian cancer will be evaluated.
- Conditions
- Ovarian Cancer
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Ovarian cancer | The patients with ovarian cancer | |
| Control group | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
thiol - disulfide levels
the rate of total thiol, native thiol and total oxidant/antioxidant capacity
Measured: April 2021 - January 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2021
- Study start9 Apr 2021
- Primary completion1 Apr 2022
- Study completion1 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 115 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tepecik Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alaattin Karabulut, Tepecik Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05011539
- Sponsor's protocol ID
- TepecikTRH-AKarabulut-001
- Status last verified
- Oct 2022
- First submitted
- 15 Aug 2021
- Last updated
- 20 Oct 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Sezgin B, Kinci MF, Pirincci F, Camuzcuoglu A, Erel O, Neselioglu S, Camuzcuoglu H. Thiol-disulfide status of patients with cervical cancer. J Obstet Gynaecol Res. 2020 Nov;46(11):2423-2429. doi: 10.1111/jog.14480. Epub 2020 Sep 9.
PubMed 32909381Karabulut A, Sanci M, Karatasli V, Kantarci S, Aydin Uysal A, Erel O, Neselioglu S, Ileri A. Thiol-disulfide homeostasis in ovarian cancer: comparative analysis with benign neoplasia and healthy women. Turk J Obstet Gynecol. 2026 Jun 4;23(2):160-166. doi: 10.4274/tjod.galenos.2026.55257. Epub 2026 Apr 15.
PubMed 41982146
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Thiol-disulfide Homeostasis in Patients With Ovarian Cancer
- ClinicalTrials.gov ID
- NCT05011539
- Acronym / sponsor ID
- TepecikTRH-AKarabulut-001
- Conditions
- Ovarian Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 115 participants (actual)
- Lead sponsor
- Tepecik Training and Research HospitalUniversity, hospital or other
- Study start
- 9 Apr 2021 (actual)
- Primary completion
- 1 Apr 2022 (actual)
- Study completion
- 1 May 2022 (actual)
- First posted
- 18 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ovarian cancer is the third most common after endometrial and cervical cancer in societies with a high standard of living; It is the second most common type of gynecological cancer after cervical cancer in societies with a low standard of living, and it is also the deadliest among gynecological cancers. Dynamic thiol-disulfide homeostasis is an antioxidant system that minimizes oxidative damage and prevents cell damage. In the presence of oxidative stress, the thiol groups combine to form the disulfide structure, and when the oxidative stress condition is over, they are separated into thiol groups again. This homeostasis is impaired in conditions that cause oxidative processes such as diabetes, cardiovascular diseases, cancers, rheumatoid arthritis, and chronic kidney failure. This can be determined by measuring the total thiol and native thiol levels. Likewise, the level of ischemia modified albumin increases in the case of oxidative stress. There are studies on this homeostasis in the literature on many types of cancer; There are studies on endometrial cancer and cervical cancer, which are gynecological cancers In this study, the usability of these tests together with other diagnostic tests in the diagnosis of ovarian cancer will be evaluated.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ovarian cancer | – | –The patients with ovarian cancer |
| Control group | – | – |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Ovarian cancer patients who applied to Izmir Tepecik Training and Research Hospital
Key inclusion criteria (1 listed)
- Histopathological diagnosis of ovarian cancer
Key exclusion criteria (3 listed)
- Having an acute or chronic disease that will cause oxidative stress
- Using alcohol/cigarettes/drugs
- Using antioxidant agents (such as vitamins A, C, E)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
thiol - disulfide levels
Time frame: April 2021 - January 2022
the rate of total thiol, native thiol and total oxidant/antioxidant capacity
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2022.
- Background: PubMed 32909381Sezgin B, Kinci MF, Pirincci F, Camuzcuoglu A, Erel O, Neselioglu S, Camuzcuoglu H. Thiol-disulfide status of patients with cervical cancer. J Obstet Gynaecol Res. 2020 Nov;46(11):2423-2429. doi: 10.1111/jog.14480. Epub 2020 Sep 9.
- Derived from this study: PubMed 41982146Karabulut A, Sanci M, Karatasli V, Kantarci S, Aydin Uysal A, Erel O, Neselioglu S, Ileri A. Thiol-disulfide homeostasis in ovarian cancer: comparative analysis with benign neoplasia and healthy women. Turk J Obstet Gynecol. 2026 Jun 4;23(2):160-166. doi: 10.4274/tjod.galenos.2026.55257. Epub 2026 Apr 15.
Related trials for Ovarian Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ovarian Cancer, run by Tepecik Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
thiol - disulfide levels (time frame: April 2021 - January 2022). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05011539, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2022.